Broadening the reach and impact of precision medicine

Cancer has always been an elusive foe, capable of evolving to evade our attempts at eradication. From genetic mutations and chromosomal instabilities to changes in key enzymes and proteins, the drivers that tumor cells rely on to survive can be exploited for therapeutic benefit – an insight that led to the first successful precision oncology therapies more than 20 years ago in an era that we call “Precision Oncology 1.0.”

We’ve come a long way from the early days of cancer therapies. Yet, the full promise of personalized medicine has not yet been realized, as only a small number of these drivers have been successfully targeted and treated with precision therapies.

Currently, about 14% of all patients with cancer are eligible for existing precision oncology therapies and only 7% realize clinical benefits.¹
We aim to change that.